Department of Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden.
Clin Exp Immunol. 2012 Jan;167(1):15-25. doi: 10.1111/j.1365-2249.2011.04469.x.
Haematopoietic stem cell transplantation (HSCT) is an immunological treatment that has been used for more than 40 years to cure a variety of diseases. The procedure is associated with serious side effects, due to the severe impairment of the immune system induced by the treatment. After a conditioning regimen with high-dose chemotherapy, sometimes in combination with total body irradiation, haematopoietic stem cells are transferred from a donor, allowing a donor-derived blood system to form. Here, we discuss the current knowledge of humoral problems and B cell development after HSCT, and relate these to the current understanding of human peripheral B cell development. We describe how these studies have aided the identification of subsets of transitional B cells and also a robust memory B cell phenotype.
造血干细胞移植(HSCT)是一种免疫治疗方法,已经使用了 40 多年来治疗各种疾病。该程序与严重的副作用相关联,由于治疗引起的免疫系统严重受损。在高强度化疗的预处理方案后,有时与全身照射联合使用,造血干细胞从供体转移,允许供体衍生的血液系统形成。在这里,我们讨论了 HSCT 后体液问题和 B 细胞发育的现有知识,并将其与对人类外周 B 细胞发育的现有认识联系起来。我们描述了这些研究如何帮助鉴定过渡 B 细胞亚群和强大的记忆 B 细胞表型。